Literature DB >> 21612403

Lysyl oxidase G473A polymorphism is associated with increased risk of coronary artery diseases.

Lan Ma1, Haihan Song, Meiyan Zhang, Daifu Zhang.   

Abstract

Lysyl oxidase (LOX) plays a crucial role in the maintenance of extracellular matrix stability and could participate in vascular remodeling associated with cardiovascular diseases. A novel polymorphism in the LOX gene, G473A (rs1800449), was identified. The objective of this study was to investigate the association between LOX G473A polymorphism and susceptibility to coronary artery diseases (CADs) in Chinese population. The LOX variant G473A was detected by polymerase chain reaction-restriction fragment length polymorphism in 656 CAD cases and 718 age-matched controls. Frequencies of LOX 473 AA genotype and A allele were significantly higher in patients with CAD than in controls (odds ratio = 1.93, 95% confidence interval 1.26-2.95, p = 0.002; and odds ratio = 1.38, 95% confidence interval 1.15-1.67, p = 0.001). Our data suggest that the G473A polymorphism of LOX gene is associated with increased susceptibility to CAD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612403     DOI: 10.1089/dna.2011.1261

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  12 in total

1.  Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease.

Authors:  Lan Ma; Haifeng Zhang; Carrie Han; Danian Tong; Meiyan Zhang; Yi'an Yao; Yu Luo; Xuebo Liu
Journal:  DNA Cell Biol       Date:  2012-02-07       Impact factor: 3.311

2.  Lysyl oxidase polymorphisms and ischemic stroke--a case control study.

Authors:  Hai-Feng Zhang; Kai-Jun Zhao; Yi Xu; Bo Hong; Wen-Yuan Zhao; Jian-Min Liu; Qing-Hai Huang
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma.

Authors:  Haihan Song; Lei Chen; Zhanshan Cha; Jianwen Bai
Journal:  DNA Cell Biol       Date:  2012-04-03       Impact factor: 3.311

4.  Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma.

Authors:  Zhanshan Cha; Yan Zang; Huijun Guo; Haihui Gu; Xiaohua Tu; Haihan Song; Baohua Qian
Journal:  Mol Biol Rep       Date:  2014-01-01       Impact factor: 2.316

5.  Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study.

Authors:  Qing Zhu; Tongtao Liu
Journal:  Mol Biol Rep       Date:  2012-06-14       Impact factor: 2.316

6.  Lack of association of lysyl oxidase (LOX) gene polymorphisms with intracranial aneurysm in a south Indian population.

Authors:  Sanish Sathyan; Linda Koshy; K R Sarada Lekshmi; H V Easwer; S Premkumar; Jacob P Alapatt; Suresh Nair; R N Bhattacharya; Moinak Banerjee
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

7.  Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.

Authors:  Lei Gao; Zhenjun Feng; Qiang Li; Lianqing Li; Lei Chen; Taiwu Xiao
Journal:  Tumour Biol       Date:  2013-11-19

8.  A Novel Association between Lysyl Oxidase Gene Polymorphism and Intracranial Aneurysm in Koreans.

Authors:  Eun Pyo Hong; Jin Pyeong Jeon; Sung Eun Kim; Jin Seo Yang; Hyuk Jai Choi; Suk Hyung Kang; Yong Jun Cho
Journal:  Yonsei Med J       Date:  2017-09       Impact factor: 2.759

9.  Lysyl oxidase polymorphisms and susceptibility to osteosarcoma.

Authors:  Yang Liu; Bitao Lv; Zhimin He; Yujia Zhou; Carrie Han; Guodong Shi; Rui Gao; Ce Wang; Lili Yang; Haihan Song; Wen Yuan
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.752

10.  Lysyl Oxidase Gene G473A Polymorphism and Cigarette Smoking in Association with a High Risk of Lung and Colorectal Cancers in a North Chinese Population.

Authors:  Guoli Wang; Yanqing Shen; Guang Cheng; Haimei Bo; Jia Lin; Maogen Zheng; Jianmin Li; Yinzhi Zhao; Wande Li
Journal:  Int J Environ Res Public Health       Date:  2016-06-28       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.